E
Eunhee Kim
Researcher at Merck & Co.
Publications - 3
Citations - 250
Eunhee Kim is an academic researcher from Merck & Co.. The author has contributed to research in topics: Brentuximab vedotin & Progressive disease. The author has an hindex of 3, co-authored 3 publications receiving 146 citations.
Papers
More filters
Journal ArticleDOI
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
Robert T. Chen,Pier Luigi Zinzani,Hun Ju Lee,Philippe Armand,Nathalie A. Johnson,Pauline Brice,John Radford,Vincent Ribrag,Daniel Molin,Theodoros P. Vassilakopoulos,Akihiro Tomita,Bastian von Tresckow,Margaret A. Shipp,Jianxin Lin,Eunhee Kim,Akash Nahar,Arun Balakumaran,Craig H. Moskowitz +17 more
TL;DR: Results confirmed the effective antitumor activity, durability of response, and manageable safety of pembrolizumab monotherapy in RRcHL, regardless of prior treatment and including chemoresistant cHL.
Journal ArticleDOI
Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma
Pier Luigi Zinzani,Hun Ju Lee,Philippe Armand,Nathalie A. Johnson,Pauline Brice,John Radford,Vincent Ribrag,Daniel Molin,Theodoros P. Vassilakopoulos,Akihiro Tomita,Bastian von Tresckow,Margaret A. Shipp,Alex F. Herrera,Jianxin Lin,Eunhee Kim,Mohammed Z.H. Farooqui,Patricia Marinello,Craig H. Moskowitz +17 more
TL;DR: Results are presented for the total population and by cohort, with an additional ~12 months of follow-up from last presentation, to evaluate pembrolizumab in patients with R/R cHL that progressed after autologous stem cell transplantation and subsequent brentuximab vedotin therapy.
Journal ArticleDOI
Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma
Pier Luigi Zinzani,Robert W. Chen,Hun Ju Lee,Philippe Armand,Nathalie A. Johnson,Pauline Brice,John Radford,Vincent Ribrag,Daniel Molin,Theodoros P. Vassilakopoulos,Akihiro Tomita,Bastian von Tresckow,Margaret A. Shipp,Eunhee Kim,Akash Nahar,Arun Balakumaran,Craig H. Moskowitz +16 more
TL;DR: Chen et al. as mentioned in this paper evaluated pembrolizumab in patients with R/R cHL that progressed after autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV) therapy.